Key result
Statin use is linked to reduced PANSS negative symptoms at 1 year in schizophrenia spectrum disorders.
Why the study?
Statins exert anti-inflammatory effects and may reduce negative symptoms in schizophrenia spectrum disorders (SSD), but findings on their efficacy remain inconsistent.
Does statin therapy initiation reduce negative symptom severity (measured by PANSS negative subscale scores) in individuals with schizophrenia spectrum disorders?
Cohort (n=3,216)
Yes
Does statin therapy initiation reduce negative symptom severity (measured by PANSS negative subscale scores) in individuals with schizophrenia spectrum disorders?
In a large real-world longitudinal cohort of patients with schizophrenia spectrum disorders, statin initiation was associated with a reduction in negative symptom severity at 1 and 3 years, independent of changes in CRP or measured metabolic parameters.
Answers are grounded in this paper and cite their sources.
Should not yet change practice for negative symptoms in schizophrenia; extends observational data but leaves causal benefit open pending RCTs.
Inflammation has been implicated in the pathophysiology of schizophrenia spectrum disorders (SSD), suggesting that anti-inflammatory strategies might offer therapeutic potential. While statins exert anti-inflammatory effects and may reduce negative symptoms, findings on their efficacy remain inconsistent. We investigated whether statin use is associated with changes in symptom severity in SSD. This longitudinal cohort study used real-world data from the Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS), an annual routine outcome monitoring program in the Netherlands. Data were collected from 2013 to 2024. Participants with SSD who were not using statins at baseline and had no recorded substance-related disorders other than cannabis or alcohol were included. Individuals who initiated statin therapy during the observational period were classified as statin users, all others were classified as non-users. Outcomes were changes in log-transformed Positive and Negative Syndrome Scale (PANSS) negative subscale scores and, secondarily, total and other subscale scores over time. Among the included participants, 264 initiated statin therapy, whereas 2,952 participants did not use statins during the study period. After one year, statin use was associated with a credible reduction in PANSS negative subscale scores (adjusted posterior mean = –0.358, 95% CI [–0.533, –0.174], PD = 1), corresponding to an approximately 3.6- point lower score when using the baseline median score of 11 as a reference. No credible evidence of mediation by C-reactive protein, LDL cholesterol, triglycerides, waist circumference, or blood pressure was observed. The association with lower negative symptom scores was also observed among patients with continued statin use over three years. Statin use was associated with reduced negative symptom severity in individuals with SSD. Beyond their established cardiometabolic benefits, statins may also have therapeutic potential for negative symptoms in SSD.
No takes yet. Share an insight, caveat, or question.
Dielemans et al. (2026) conducted a cohort in Schizophrenia spectrum disorders (n=3,216). Statin therapy initiation vs. Non-statin users was evaluated on Change in log-transformed Positive and Negative Syndrome Scale (PANSS) negative subscale score after 1 year (Adjusted posterior mean -0.358, 95% CI -0.533 to -0.174). Statin use was associated with a reduction in log-transformed PANSS negative subscale scores at 1 year in schizophrenia spectrum disorders.
Synapse has enriched 10 related papers. Consider them for comparative context: